CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-Tumor Effects Mediated by Alloreactive CD8 T Cells
Author Information
Author(s): Liu Kechang, Anthony Bryan A., Yearsly Martha M., Hamadani Mehdi, Gaughan Alice, Wang Jiao-Jing, Devine Steven M., Hadley Gregg A.
Primary Institution: The Ohio State University
Hypothesis
CD103 deficiency can prevent GVHD pathology without compromising tumor immunity mediated by alloreactive CD8 T cells.
Conclusion
CD103 deficiency inhibits GVHD pathology while preserving anti-tumor effects mediated by CD8 T cells.
Supporting Evidence
- CD103 deficiency dramatically attenuated GVHD mortality.
- Donor CD8 T cells from wild-type mice induced GVHD pathology.
- CD103 was preferentially expressed by CD8 T cells infiltrating the host intestinal epithelium.
Takeaway
This study found that removing a specific protein called CD103 from immune cells can stop harmful reactions in the body after a transplant, while still allowing those cells to fight tumors.
Methodology
An alloSCT model was developed using purified CD8 T cells to assess the impact of CD103 on GVHD and GVT effects.
Limitations
The study primarily used a mouse model, which may not fully replicate human responses.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website